Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novartis to Buy Alcon for $39B

By Drug Discovery Trends Editor | January 4, 2010

BASEL, Switzerland (AP) – Novartis AG said it plans to take over Alcon Inc. by paying $38.5 billion for the 77 percent stake it does not already own in a deal that would make it one of the biggest players in the global market for eye-care products.

The Swiss pharmaceutical company will purchase Nestle SA’s 52 percent stake for $28 billion, or $180 per share, before carrying out a merger with Alcon that would give it control of the remaining 23 percent held by minority shareholders.

The Basel-based drug maker had already purchased 25 percent of Alcon from Nestle in April 2008 for $11 billion, with the option of buying the food and drinks company’s remaining stake at a later date.

If successful, the takeover will have cost about $50 billion in all, making it the biggest in Swiss corporate history.

“This is the right time to simplify Alcon’s ownership to eliminate uncertainties for employees and shareholders,” said Novartis chairman and chief executive Daniel Vasella.

“It will also allow us to strengthen innovation power by combining R&D efforts and grow our global market presence thanks to our complementary product portfolios,” he said in a statement.

Vasella told reporters in a conference call Monday that the takeover represents a “great strategic fit.”

Novartis shares were down 1 percent at 55.90 Swiss francs ($54.07) in morning trading on the Zurich exchange.

Analysts welcomed the announcement but said Novartis might have to raise its offer to win over Alcon minority shareholders. Andrew Woods of Sanford C. Bernstein said Novartis’ decision to exercise its option “probably has to do with its strategy of bidding for the remaining 23 percent of the shares outstanding.”

Under the terms of the merger proposal, minority shareholders would receive 2.8 Novartis shares for each Alcon share. Based on the Novartis share price and exchange rates prior to the announcement, this would value each publicly traded share of Alcon at approximately $153, Alcon said.

Alcon said a committee composed of its three independent board members has engaged financial and legal counsel to evaluate the proposed merger. The deal also requires regulatory approval.

Alcon is based in Huenenberg, Switzerland, and has its U.S. headquarters in Fort Worth, Texas. The company employs some 15,000 people worldwide and specializes in surgical equipment and devices, contacts lens solutions and other consumer eye-care products. It posted a net profit of $515 million, or $1.71 per share, in the third quarter.

By merging Alcon into its existing eye-care portfolio, which includes the Ciba Vision brand, Novartis said it would be able reach 70 percent of the world market.

Vasella said Novartis would save an additional $100 million on top of $200 million savings it had already predicted within three years of the merger. Novartis doesn’t plan to cut any jobs, Vasella said.

Nestle purchased Alcon in 1977 for $280 million. In total, the Vevey-based company has earned over $40 billion from the sale of Alcon.

Date: January 4, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE